Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
June 01 2022 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will present in a
fireside chat at the Jefferies Healthcare Conference on Wednesday,
June 8, 2022 at 8:00 AM ET at the Marriott Marquis in New York,
NY.
In addition to the presentation, the management team will host
investor meetings. Investors participating in the conference who
are interested in meeting with Ocular Therapeutix management should
contact their Jefferies representative.
A live webcast of the presentation will be available and can be
accessed by visiting the Investors section of the Company’s website
at investors.ocutx.com. It will be available for replay for 90
days.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation,
development, and commercialization of innovative therapies for
diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s first commercial drug product, DEXTENZA®, is an
FDA-approved corticosteroid for the treatment of ocular
inflammation and pain following ophthalmic surgery and ocular
itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and other retinal diseases;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials. Ocular Therapeutix's
first product, ReSure® Sealant, is an FDA-approved device to
prevent wound leaks in corneal incisions following cataract
surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220601005448/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
ICR Westwicke Chris Brinzey, 339-970-2843 Managing Director
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2023 to Apr 2024